ANIP (ANI Pharmaceuticals) Other Long Term Assets: $78.1 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIP ANI Pharmaceuticals Inc ANIP
80 GF Score
Price $78.45
GF Value $101.81
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ANI Pharmaceuticals Other Long Term Assets?

ANI Pharmaceuticals ANIP -5.35% 80 Other Long Term Assets is $78.1 Mil as of Mar. 2026. GuruFocus rates ANIP with a GF Score™ of 80/100 and a GF Value™ of $101.81 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ANI Pharmaceuticals's other long-term assets for the quarter that ended in Mar. 2026 was $78.1 Mil.

ANI Pharmaceuticals's quarterly other long-term assets declined from Sep. 2025 ($83.9 Mil) to Dec. 2025 ($82.8 Mil) but then stayed the same from Dec. 2025 ($82.8 Mil) to Mar. 2026 ($78.1 Mil).

ANI Pharmaceuticals's annual other long-term assets declined from Dec. 2023 ($102.8 Mil) to Dec. 2024 ($97.3 Mil) and declined from Dec. 2024 ($97.3 Mil) to Dec. 2025 ($82.8 Mil).

ANI Pharmaceuticals Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for ANI Pharmaceuticals's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ANI Pharmaceuticals Other Long Term Assets Chart

ANI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.14 92.72 102.78 97.33 82.78

ANI Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.80 100.27 83.89 82.78 78.13
ANIP
80GF Score
ANI Pharmaceuticals Inc ANIP
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ANI Pharmaceuticals Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $78.1 Mil mean?
ANI Pharmaceuticals (ANIP) has a Other Long Term Assets of $78.1 Mil as of Mar. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on ANI Pharmaceuticals and its competitors.
Is ANI Pharmaceuticals' Other Long Term Assets too high?
ANI Pharmaceuticals' current Other Long Term Assets is $78.1 Mil. Overall, ANI Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' Other Long Term Assets compare to TRLV and AMLX?
ANI Pharmaceuticals' Other Long Term Assets of $78.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on ANI Pharmaceuticals and its competitors. ANI Pharmaceuticals's current Other Long Term Assets is $78.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (ANIP) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.81, compared to a current price of $78.45 — trading 22.9% below its estimated fair value. The current Other Long Term Assets is $78.1 Mil. ANI Pharmaceuticals' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For ANI Pharmaceuticals (ANIP), the current Other Long Term Assets is $78.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ANI Pharmaceuticals (ANIP) Overvalued in 2026?

Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued. The current stock price of $78.45 is trading 22.9% below its estimated GF Value™ of $101.81. GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for ANIP:

  • Other Long Term Assets: $78.1 Mil
  • GF Value™: $101.81 vs. price of $78.45 (22.9% below fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the ANIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ANI Pharmaceuticals Business Description

Other Exchanges BSFA:Germany
Address 210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
80GF Score

Get the complete analysis for ANIP

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$78.45
Price
$101.81
GF Value